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Abstract 
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Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions 
is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood 
environment for processing and energy supply in liver and other organs. In this study, the genomic 
area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) 
using the in vitro data-based computer program. Several new putative REs were found in 
surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the 
PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines 
were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, 
APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary 
manners. Those results provide new insights in the understanding of lipid metabolism and so many 
lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke.  
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Abbreviations 
APO  apolipoprotein 
ARP0  acidic riboprotein P0 
ChIP  chromatin immunoprecipitation 
Chr  chromosome 
CoA  coactivator 
CoR  corepressor 
DBD  DNA-binding domain 
DMSO  dimethylsulfoxide 
DR  direct repeat 
ER  everted repeat 
FBS  fetal bovine serum 
Gln  glutamine 
GO  gene ontology 
GW501516 2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)1,3thiazol-5-yl)-
methylsulfanyl)phenoxy-acetic acid 
GW7647 2-(4-(2-(1-cyclohexanebutylcyclohexyllureido)ethyl)phenylthio)-2-
methylpropionicacid 
HDL  high density lipoprotein 
HEK293  human embryonic kidney epithelia cell line 
HepG2  human hepatoma derived cell line 
IDL  intermediate density lipoproteins 
IGF  insulin-like growth factor 
IgG  immunoglobulin G 
IR  inverted repeat 
kB  kilo base pairs 
Kd  dissociation constant 
kDa  kilo Dalton 
LBD  ligand-binding domain 
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LBP  ligand-binding pocket 
LDL  low density lipoprotein 
LIPE  hormone sensitive lipase 
LPL  lipoprotein lipase 
LRP  lipoprotein receptor-related protein 
LXR  liver X receptor 
NR  nuclear receptor 
PPAR  peroxisome proliferator-activated receptor 
p-PolII  phosphorylated RNA polymerase II 
PPRE  PPAR response element 
RAR  retinoic acid receptor 
RE  response element 
Rosiglitazone 5-[4-[N-methyl-N-(2pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-
dione 
RXR  retinoid X receptor 
TF  transcription factor 
Trap220  thyroid receptor-interacting protein 2 
TSS  transcription start site 
VDR  vitamin D receptor 
VLDL  very low-density lipoprotein 
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1. Introduction 
1.1 Nuclear receptors in general – an overview 
Human nuclear receptors (NRs) form a superfamily of 48 members. NRs are transcription factors 
(TF), many of which are ligand-activated and regulate the expression of specific target genes 
involved in many essential processes, such as reproduction, development and general metabolism 
(Chawla et al., 2001). Their ligands are either high-affinity hormonal lipids or low-affinity dietary 
lipids, all which are able to penetrate cellular membranes and reach their receptors in the nucleus or 
cytosol directly. Also some unexpected ligands have been suggested for NRs, such as glucose for 
the liver X receptor and PPARs (Mitro et al., 2007, Hostetler et al., 2008). Like other TFs, NRs 
work in a concert with coactivators (CoAs) and corepressors (CoRs) to achieve primary chromatin 
remodeling events, which lead to activation or suppression of target gene expression (Glass and 
Rosenfeld, 2000).  
When NRs are in the nucleus and bound to DNA, they modulate transcription by recruiting 
coregulators and components of the basal transcriptional machinery. When the receptor has no 
ligand, it recruits transcription-repressing factors known as CoRs to the target gene promoters 
(Bowen et al., 2004). CoRs, such as nuclear corepressor (NCoR), recruit histone deacetylases 
(HDACs). ATP-dependent remodeling complexes (ADCRs), such as the nucleosome remodelling 
and histone deacetylase complex (NURD), are also recruited by NRs in their repressive state to 
silence transcription by affecting chromatin structure in an ATP-dependent manner (Xue et al., 
1998). Together these factors create a chromatin environment that actively reduces transcription. 
When a specific ligand binds the receptor, it undergoes a conformational change, which leads to 
CoR abolishment and CoA recruitment (Glass and Rosenfeld, 2000). CoAs can affect in different 
ways. Certain CoAs form a protein bridge between TFs and the basal transcription machinery 
enabling the communication between the distal enhancer elements and the proximal promoter 
(Lewis and Reinberg, 2003). Thus, TFs play an important role in gene expression. 
The similar structural organisation of NRs (Figure 1) defines the superfamily and reflects their 
function as ligand-regulated TFs (Mangelsdorf et al., 1995). The variable N-terminal domain 
contains in most NRs a ligand-independent transcription activation function (AF-1) (Folkertsma et 
al., 2004). Moreover, NRs contain a highly conserved DNA-binding domain (DBD) of 
approximately 70 amino acid residues and also conserved ligand-binding domain (LBD) of 
approximately 250 amino acid residues. In general, the N-terminal and linker areas of NR proteins 
are not conserved. The interaction with CoAs and CoRs is controlled via helix 12 (AF-2).
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Figure 1. Schematic representation of general structure of a NR (according to Folkertsma et al., 2004). NRs 
contain five domains. The variable N-terminal domain contains the ligand-independent activation function 1 (AF-1). 
The conserved DBD recognizes response elements (REs) in target genes. The short variable linker area connects the 
DBD to the structurally conserved LBD, which is responsible for the ligand specific functions. The activation function 2 
(AF-2) –domain (helix 12) is ligand-dependently recruiting coregulators. 
 
The NR superfamily can be divided into three district groups (Table 1) (Chawla et al., 2001, 
Germain et al., 2006). The first group consists of the classical endocrine receptors, which include 
the receptors for 3,5,3’triiodothyronine (thyroid hormone receptor, TR), all-trans retinoic acid 
(retinoic acid receptor, RAR), 1α,25dihydroxyvitamin D3 (1α,25(OH)2D3) (vitamin D receptor, 
VDR), 17β–estradiol (estrogen receptor α and β, ER), cortisol (glucocorticoid receptor, GR), 
aldosterone (mineralocorticoid receptor, MR), progesterone (progesterone receptor, PR) and 
dihydrotestosterone (androgen receptor, AR). Those classical endocrine receptors bind their ligands 
at high affinity with a dissociation constant (Kd) of 0.1 to 1 nM (Chawla et al., 2001). For adopted 
orphan NRs ligands have been subsequently identified. Members of this group include receptors for 
fatty acids (peroxisome proliferator–activated receptors, PPARs), oxysterols (liver X receptor, 
LXR), bile acids (farnesoid X receptor, FXR) and xenobiotics (pregnane X receptor, PXR and 
constitutive androstane receptor, CAR). The ligands are low-affinity dietary lipids like cholesterol 
derivatives and bile acids with a Kd up to 10 μM (Chawla et al., 2001). Adopted orphans preferably 
bind DNA as heterodimers with retinoid X receptor (RXR), which itself is a member of this second 
subgroup. For the remaining NRs (21), the so-called true orphan, no ligand has yet been identified. 
Phylogenic analyses of the NR superfamily indicate that the first NRs may have been true orphan 
and a ligand has been adapted at a later step in evolution (Escriva et al., 2000). This observation 
suggests that some of the present orphan NRs have still not acquired a ligand or there are 
undiscovered ligands for many present orphans (Ingraham et al., 2005). The true orphan NRs prefer 
to bind DNA as homodimers, some as RXR-heterodimers and some, like the estrogen-related 
receptor α (ERRα), as monomers (Giguère, 1999). The physiological significance of many orphan 
receptors is poorly known, but they are definitely active bodies in development and adult 
physiology and they often regulate the action of classic liganded receptors (Benoit et al., 2006). 
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Table 1. The human NRs and their ligands (adapted from Germain et al., 2006). 
Subfamily Name Ligand(s) 
   
Endocrine receptors,  GR Cortisol, dexamethasone, RU486 
receptors with high  MR Aldosterone, spirolactone 
affinity for ligand PR Progesterone, medroxyprogesterone acetate, RU486 
 AR Testosterone, flutamide 
 ERα Estradiol-17, tamoxifen, raloxifene 
 ERβ Estradiol-17, various synthetic compounds 
 RARα,β,γ All-trans retinoic acid 
 TRα,β Thyroid hormones 
 VDR Vitamin D, lithocholic acid 
   
Adopted orphan  RXRα,β,γ 9-cisretinoic acid 
receptors, PPARα Fatty acids, leukotriene B4, fibrates 
receptors with low  PPARβ Fatty acids 
affinity for ligands PPARγ Fatty acids, prostaglandin J2, thiazolidinediones 
 LXRα,β Oxysterols, T0901317, GW3965 
 FXR Bile acids, fexaramine 
 PXR Xenobiotics, 16 -cyanopregnenolone 
 CAR Xenobiotics, phenobarbital 
 ERRβ,γ DES, 4-OH tamoxifen 
 RORα Cholesterol, cholesteryl sulfate 
 RORβ Retinoic acid 
   
Orphan receptors, SF-1  
receptors without LRH-1  
ligand DAX-1  
 SHP  
 TLX  
 PNR  
 GCNF  
 HNF-4  
 TR2, 4  
 NGF1-Bα,β,γ  
 RORγ  
 RVRα,β,γ  
 ERRα  
 COUP-TFα,β,γ  
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   NN   
 
n = 0  GCNF-GCNF      
                      
n = 1  RXR-RXR       
       COUP-COUP 
       HNF-4-HNF-4 
       PPAR-RXR 
 
n = 2  RevErbA-RevErbA 
       TR2-TR2 
 
n = 3  RXR-VDR 
 
n = 4  RXR-TR 
       RXR-LXR 
       RXR-CAR 
       RXR-PXR 
       RXR-VDR 
 
n = 5  RXR-RAR 
       RXR-NGFI-B
  5'-motif 
 
    RGKTCA
  3'-motif 
 
    RGKTCA
 
   
n  
 
  
NN  
 
 
  
    
   
 
RGKTCA
   
 
TGAMCY
 
   1 
 
 ER-ER 
 FXR-RXR 
 ERR-ERR 
 
   
   3 
 
 GR-GR 
 MR-MR 
 PR-PR 
 AR-AR 
   
 
RGAACA
   
 
TGTTCY
Direct repeat (DRs)            Inverted repeats (IRs)
   
 
RGKTCA
   
 
TCAMCY
 
   6-9 
 
 
Everted repeats (ERs)
 
 
 
 RXR-VDR 
  
NRs bind DNA through zinc-finger motifs (zinc-finger C4-type) in their DBD. The DBD of all NRs 
contains two α-helices perpendicular to each other (Shaffer and Gewirth, 2002; Carlberg, 2004). 
One of these α-helices is located behind the zinc finger and so is inserted into the major groove of a 
hexameric DNA sequence. Since the recognition helix is highly conserved throughout the NR 
family, almost all NRs recognize common DNA sequences. These sequences, mostly formed by 
two hexamers, are called REs. The hexameric REs are distinguished into three different 
configurations: direct repeats (DRs) inverted repeats (IRs) and everted repeats (ER) (Figure 2). The 
general consensus NR RE sequence is RGKTSA (R = A or G, K = G or T, S = C or G) (Carlberg, 
1995). This is, however, not true for AR, GR, MR and PR NRs, which bind the sequence RGAACA 
(Germain et al., 2006). In general, most members of the NR superfamily bind DNA either as homo- 
or intra-familial heterodimeric complexes on REs that are found by two hexameric binding 
complexes spaced by different numbers of nucleotides (Mangelsdorf and Evans, 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The types of REs (according to Carlberg et al., 2004). The most preferred RE for each type of homo- or 
heterodimeric NR complex is shown. “NN” represents 5'-flanking sequences and “n” amount of nucleotides between 
the hexameric NR bidning sequences. 
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1.2 Screening of TFs binding sites 
Fields such as genomics and systems biology are built on the synergism between computational and 
experimental techniques. This type of synergism is especially important in accomplishing goals like 
identifying all functional transcription factor binding sites in vertebrate genomes. Positional 
information on TF binding sites in whole genomes is useful to identify target genes of specific TFs. 
Furthermore, such information is helpful to generate models on the regulation of genes that are 
investigated. Since the completion of the first draft sequence of the humangenome in 2001, in silico 
methods have been used to find TFs binding sites. 
The most obvious application of finding TFs is the weight matrix (WM). WM, where known, 
experimentally defined binding sites collected from publications are aligned and used to form a 
matrix that represents the frequencies of four DNA bases in TFs binding sites (Stormo, 2000). They 
are easy to use and so then are come really popular. WM is easy to generate but then the problem is 
to determine whether the sequence is likely to be sampled from the matrix or not. This is done by 
use of threshold value which is crucial to the false detection level of TF binding sites. 
Recently, alternatives methods that exploit experimental binding data set were developed (Hallikas 
and Taipale, 2006). Those scoring matrices perform well in the detection of near consensus REs 
variants and also approximates, to a certain extant their relative binding strengths. This is essential, 
when are talking about NRs. Without elegant fine adjustment of in silico screening it is easy to lose 
or mix up interesting findings. There is still a clear need to incorporate biological knowledge and 
principles into the methods in order to elucidate the findings of the in silico screening. 
 
1.3 Peroxisome proliferator-activated receptors 
In the early 1990s the PPARs were cloned. They were the first NRs that mediate effects of synthetic 
compounds. The first member, PPARα, was found responsive to peroxisome proliferators, in liver 
of rodents (Issemann and Greese. 1990). Three PPAR subtypes have been identified, α, γ and δ/β, 
which show a tissue-specific expression pattern. PPARα is highly expressed in brown adipose tissue 
and liver and to a lesser extend in kidney, heart and skeletal muscle. PPARγ is mainly expressed in 
adipose tissue and plays an important role in adipocyte differentiation and lipid storage. PPARγ is 
present at low levels in skeletal muscle; it can be also detected in macrophages, where it induces 
their differentiation and where it is involved in lipid efflux. PPARδ/β is found in many tissues, but 
it shows the highest expression in the gut, kidney and heart (Desvergne and Wahli, 1999). All three 
PPARs are also involved in different aspects of inflammation (Kostadinova et al., 2005). In general, 
the functions of all three PPARs are overlapping to each other and even with that of other NRs. 
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PPARs belong to the adopted orphan receptor group of the NR superfamily. Like the other members 
of the family, PPARs are considered to be ligand-dependent TFs, meaning that activation of the 
target gene depends on the binding of the ligand to the receptor. However, recently evidence for a 
ligand-independent association with cofactors was shown (Molnár et al., 2005). Some ligands are 
shared between the three subtypes, such as polyunsaturated fatty acids and oxidized fatty acids 
(Kersten et al., 2000a). An alternative activation pathway of PPAR-RXR heterodimers occurs 
through ligand binding to RXR. The natural RXR ligand, 9-cis retinoic acid, as well as synthetic 
RXR-selective compounds can activate a PPRE– driven reporter gene in a PPAR-RXR-dependent 
manner (Desvergne and Wahli, 1999, Feige et al., 2005). 
 
1.3.1 PPREs 
PPREs are comprised of a direct repeat of two core recognition motifs, AGGTCA, spaced by one 
nucleotide, so-called DR1-type REs (Kliewer et al., 1992). The first natural PPRE was found in the 
promoter of the acyl-CoA oxidase gene and all subsequently identified natural PPREs fulfil this 
DR1 criterion (Dreyer et al., 1992; Tugwood et al., 1992). However, this definition has specified 
later on: an extended 5’ – half site, an imperfect core DR1 and an adenine as the spacing nucleotide 
between the two hexamers have been proposed as further determinants of PPREs (IJpenberg et al., 
1997). 
PPARs regulate transcription as heterodimers with RXRs. The receptor dimer binds the REs with 
PPARs occupying the 5'-hexamer (Glass, 1994). This is the abnormal binding order of NR-RXR 
heterodimers. For different NRs an influence of the 5’-flanking sequence is discussed. The 5’-
flanking effect has been shown on constitutive androstane receptor (CAR) (Frank et al., 2003). Also 
for PPARs, especially for PPARα, it looks that an extended 5’–flanking sequence of seven 
nucleotides influences DNA binding, and thus may contribute to the subtype specificity (Juge-
Aubry et al., 1997). Some PPAR target genes with known PPREs and in silico defined binding 
strength are listed in table 2. 
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Table 2. List of the some known human PPAR target genes with their PPREs. REs location to the TSS and relative 
strength to the consensus sequence where consensus is 100 and receptor is PPARγ. Adapted from (Heinäniemi et al., 
2007). 
Gene Sequence Location REs class and relative strength 
ACBP GGGACAGAGGTCC -957 None 
ACOX1 AGGTCACTGGTCA -1918 None 
ADRP AGGTGAAAGGGCG -2357 Strong (40) 
APOA1 GGGGCAGGGGTCA -214 None 
APOA2 AGGGTAAAGGTTG -734 Weak (1) 
APOA5 AGGTTAAAGGTCA -271 Strong (70) 
APOC3 TGGGCAAAGTTCA -87 Weak (5) 
APOE AGGGGAAGGGTCA 5655 Strong (40) 
CPT1β AGGGAAAAGGTCA -774 Strong (40) 
CPT2 GTGCTGAAGGTCA -97 None 
CYP1A1 GGGGCAGAGGTCA, AGCCCTGAGGTCA -931, -531 Weak (3), None 
CYP27A1 CGCCCAGAGTTCA -291 None 
FIAF AGGGGAAAGGTCG 3270 Strong (40) 
FXR AGGTCAAGTGCCA, TGTCCATGAGGCA -239, -80 Weak (5), None 
GSTA2 AGGTCATCACCGA, GCAGGAAGGATCA AGGACAAAGATTA -792, -746, -549 None, None, None 
I-BABP GCCAGCAGGGTCA -198 None 
I-BAT AGGCCAGAGGTCA -1577 Weak (3) 
Insig-I AGCCAGAAGGTCA -757 None 
LXRα CGTACAAAGTTCA -2216 None 
P16 AGGAGACAGGACA -1023 None 
PEX11A GGGTGAGAGGTGA -8400 Weak (3) 
PLTP GGGTCAGTGACCCA -339 None 
PXR AGGACAGAGCTCT -1350 None 
Resistin GAGGAGAAAGTTC -2102 None 
SR-B1 AGGAGAAAGGGGA -472 Weak (5) 
SULT2A1 AGGTGAAAGGTAA -5949 Strong (70) 
Transferrin AGGTCAAGATTG -76 None 
UCP3 GGTTTCAGGTCAG, TGACCTTTGGACT -67, -281 None, Strong (20) 
UGT1A9 AAATCAGAGGTGA -719 None 
UGT2B4 AGATTAAAGTTCA -1193 None 
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1.3.2 PPARα 
Several compounds bind with high affinity to PPARα, including long-chain unsaturated fatty acids, 
such as linoleic acid, branched, conjugated and oxidized fatty acids, such as phytanic acid and 
conjugated linoleic acid, and eicosanoids, such as leukotriene B4 (Desvergne and Wahli, 1999). 
Also, synthetic ligands from the fibrate family, such as GW7647 (2-(4-(2-(1-Cyclohexanebutyl-3-
cyclohexylureido)ethyl)phenylthio)-2- methylpropionic acid), activate the receptor. 
Much of the function of PPARs can be extrapolated from the identity of their target genes, most of 
which belong to lipid transport and metabolism pathways (Planavila et al., 2006). PPARα has 
mostly been studied in the context of liver. The target genes of PPARα are a relative homologous 
group of genes that participate in aspects of lipid catabolism, such as fatty acid uptake through 
membranes, fatty acid binding in cell, fatty acid oxidation (in microsomes, peroxisomes and 
mitochondria) and lipoprotein assembly and transport (Kersten et al., 2000b). However, extensive 
lists of direct targets, for which binding sites have been identified, exist only for mouse PPARα, but 
not in human (Mandard et al., 2004). To use fatty acids in energy production requires the uptake of 
free fatty acids carried by lipoproteins. In the mouse liver, PPARα up-regulates the fatty-acid 
transport protein-1. Also the CD36 gene (APO receptor) has been described as a target of PPARα 
in human and mouse (Frohnert et al., 1999; Sato et al., 2002). 
The long-chain fatty acyl-CoAsynthetase gene is described as target of PPARα in rat (Schoonjans., 
et al 1996). This gene is responsible of fatty acid translocation in mitochondria. PPARα is 
increasing β–oxidation by up-regulating acyl-CoA-oxidase (ACOX1), which has an orthologous 
PPAR-regulated human gene (Tugwood et al., 1992; Varanasi et al., 1996). So PPARα not only 
stimulates energy production, but also shortens long-chain fatty acids thus preventing lipid 
accumulation and toxicity. Moreover, PPARα up-regulates the apolipoprotein (APO) genes APOAI 
and APOA2, which are the major compound of high density lipoprotein (HDL) (Vu-Dac et al., 
1994; Vu-Dac et al., 1995). PPARα is also up-regulating HDLs surface protein phospholipid 
transfer protein (LPL) and receptor, which is located in liver cells outer membrane scavenger 
receptor-class B type I (SR-BI) (Malerød et al., 2003). PPARα is down-regulating APOC3, which is 
an elevating triglyceride level by secondary effects (Hertz et al., 1995; Li et al., 1995). Finally, the 
human APOA5 gene, which is involved the maintenance of normal triglyceride level, is a direct 
PPAR target (Prieur et al., 2003). 
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1.3.3 PPARγ 
PPARγ is activated by ligands of the glitazone class, like troglitazone, pioglitazone and 
rosiglitazone (5-((4-(2-(methyl-2-pyridinylamino) ethoxy)phenyl)methyl)- 2,4-thiazolidinedione), 
which are used for the treatment of type 2 diabetes (Kallen and Lazar, 1996; Maeda et al., 2001). 
Natural PPARγ ligands are 15-deoxy-Δ12,14-prostaglandine J2 and also linoleic acid acts as an 
activator for this receptor (Krey et al., 1997). 
In humans there are two isoforms of PPARγ. The longer isoform PPARγ2 has 28 additional amino 
acids in the N-terminus and has been characterized as the master regulator of the formation of fat 
cells and their normal function (Barak et al., 1999; Rosen et al., 1999). PPARγ2 influences mainly 
the storage of fatty acids in the adipose tissue to gether with the CCAAT/enhancer binding proteins 
(C/EBPs), especially C/EBPα. PPARγ2 is part of the adipocyte differentiation program that induces 
the maturation of pre-adipocytes into fat cells (Farmer, 2005, Darlington et al., 1995, Tontonoz et 
al., 1995a; Tontonoz et al., 1994b). Most of the PPARγ target genes in adipose tissue are directly 
implicated in lipogenic pathways.  
PPARγ promotes insulin sensitivity through altering the communication between adipocytes, 
muscle and liver cells by inducing the expression of the insulin-sensitizing factor adiponectin, but 
PPARγ is also linked to insulin resistance by lipotoxicity hypothesis (Kershaw and Flier, 2004). It 
states that abnormal accumulation of triglycerides and fatty acyl-CoA in both muscle and liver cells 
can result in insulin resistance (Shulman, 2000). The system by which insulin is regulated and fine-
tuned by PPARγ is not fully understood. 
The immune system and inflammation reactions play a critical role in development of 
atherosclerosis. Recently, PPARγ agonists have been found to improve the symptoms of the 
disease. The main impact of PPARγ is the prevention of the transformation of macrophages into 
foam cells. Oxidized low-density lipoproteins (ox-LDL) are cumulating in macrophages, which 
causes transformation into foam cells. Foam cells secrete cytokines that promote inflammatory 
reaction and smooth muscle cell proliferation. PPARγ has been shown to counteract these processes 
(Frohnert et al., 1999; Chawla et al., 2001a; Sato et al., 2002). 
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1.3.4 PPARδ/β 
PPARδ/β binds both unsaturated and saturated fatty acids, but with lower affinity than PPARα. 
Also for this receptor synthetic ligands exist. One example is GW501516 (2-Methyl-4-((4-methyl-
2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)-methylsulfanyl)phenoxy-acetic acid). 
PPARδ/β is required for placental development and is involved in the control of lipid metabolism. 
The best-characterized function of PPARδ/β is the role in the control of cell proliferation, 
differentiation and survival, especially in keratinocytes (Tan et al., 2001; Tan et al., 2002). The 
receptor exerts its anti-apoptotic functions through increased expression of the integrin like kinase 
(ILK) and the pyruvate dehydrogenase kinase 1 (PDK1) genes, which are important in signalling 
pathways that control cell adhesion, proliferation and survival (Yin et al., 2006; Burdick et al., 
2007). ILK and PDK1 phosphorylate and activate the survival factor AKT1 (Di-Poï et al., 2002). 
Because all of these proteins are ubiquitously expressed, it is likely that PPARδ/β participates in the 
regulation of many cell functions that are involved in the development of tumors, when 
uncontrolled. In addition, PPARδ/β has a role in skin and wound healing (Wahli, 2002). 
 
1.4 Lipids and lipoproteins 
Lipids are fat-soluble, naturally-occurring molecules, such as fats, oils, waxes, cholesterol, sterols, 
fat-soluble vitamins (vitamins A, D, E and K), monoglycerides, diglycerides, phospholipids and 
others. The main biological functions of lipids include energy storage, acting as structural 
components of cell membranes, and being important signalling molecules. Lipids also encompass 
fatty acids and their derivatives as well as other sterol-containing metabolites like cholesterol. 
Lipids play diverse and important roles in nutrition and health. Many lipids are vital for life. 
However, there is also considerable awareness that abnormal levels of certain lipids are risk factors 
for many common diseases in industrial countries. High fat intake contributes to increased risk of 
obesity and so risk of metabolic syndrome, diabetes and atherosclerosis. 
A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their 
derivatives may be covalently or non-covalently bound to the proteins. Many enzymes, transporters, 
structural proteins, antigens, adhesins and toxins are lipoproteins. Examples include the high 
density and low density lipoproteins of the blood, the transmembrane proteins of the mitochondrion 
and the chloroplast. Lipoproteins in the circulation carry hydrophobic lipids in the water/salt-based 
blood environment. The protein particles have charged groups on their surface and non-polar groups 
inward, so that triglyceride-fats and cholesterol are carried internally, shielded by the protein 
particle from the water. 
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1.4.1 Lipoprotein metabolism 
Lipids that are absorbed from food by the intestine are dissolved in body fluids and then transported 
all over the body (Figure 3). In the exogenous pathway, dietary esterified triacylglycerols and 
cholesterol are combined with apolipoprotein B-48 (APOB-48), phospholipid and free cholesterol 
to produce nascent chylomicrons in the enterocyte (Karpe at al., 1996). Chylomicron particles (CM) 
are then secreted into lymphatic vessels and flow into the circulation, where they acquire 
apolipoprotein E (APOE) and apolipoprotein C2 (APOC2) from other lipoproteins (Redgrave, 
1983). Lipoprotein lipase (LPL) is activated by APOC2, which causes triacylglycerols to break 
from chylomicrons. After chylomicrions enzymatic processing chylomicron remnants (CR) remain 
and they are then removed from the circulation by hepatic APOE/APOB receptors (LRP (LDL-
related protein), LDL-R (LDL receptor)). 
In the endogenous pathway very low-density lipoproteins (VLDLs) transport hepatically 
synthesized triacylglycerols and cholesterol in the circulation to extrahepatic tissues (Mahley et al., 
1984). Nascent VLDLs circulate in blood and pick up APOC2 and APOE donated from high-
density lipoproteins (HDLs). At this point, the nascent VLDL becomes a mature VLDL. Nascent 
VLDLs contain one molecule of apolipoprotein B-100 (APOB-100) per particle. VLDLs differ in 
size according to their triacylglycerol content. The larger VLDL pieces are hydrolyzed by LPL, 
which is activated by APOC2 and inhibited by apolipoprotein C3 (APOC3), hydrolysis of the 
VLDL particle releases glycerol and fatty acids (Shachter, 2001). Most of the remnant particles 
formed by this process are removed directly by the liver. Some larger VLDL species are, however, 
subjected to further LPL-mediated lipolysis, resulting in the formation of small dense LDL 
particles. The hydrolyzed VLDL particles are now called intermediate density lipoproteins (IDLs) 
or VLDL remnants. IDLs can circulate and, via an interaction between APOE and the LDL receptor 
and/or LRP, be absorbed by the liver, or they can be further hydrolyzed by hepatic lipase converting 
to IDL remnants, which are also called low density lipoproteins (LDLs) (Chappell and Medh, 
1998). LDLs are the major carrier of cholesterol in the circulation. The cellular uptake and 
degradation of LDL particles is facilitated by a saturating mechanism involving the interaction of 
the APOB-100 component of LDL with LDL receptors. 
In humans, excess cholesterol from peripheral tissue is transported back to the liver by a process 
called reverse cholesterol transport (RCT) (von Eckardstein et al., 2001). Apolipoprotein A1 
(APOA1) discs are produced by enterocytes and hepatocytes or dissociate from triacylglycerol-rich 
lipoproteins following lipolysis by LPL. The lipid-poor APOA1-containing particles interact with 
peripheral cells and acquire phospholipids and free cholesterol (FC) through ATP-binding cassette 
protein A (ABCA1), and possibly by scavenger receptor B1 (SR-B1) (Bewer, 2004). Phospholipid 
transfer protein (PLTP) also facilitates the first step of RCT by transferring phospholipids from 
cellularmembranes and lipoprotein surfaces to form pre-HDLs (Fielding and Fielding, 1995). Once 
associated with nascent HDL, free cholesterol is esterified by the enzyme lecithin:cholesterol 
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acyltransferas (LCAT). The nascent HDL (pre-HDLs) particles are converted into spherical small 
dense HDL3. The maturation of HDL3 particles requires further acquisition of free cholesterol and 
subsequent cholesterol esterification converts HDL3 into larger, less dense cholesterol-rich HDL2 
particles. The majority of free cholesterol in HDL can be taken up selectively by the liver through 
the action of SR-B1. Cholesteryl ester can also be selectively transferred to APOB-containing 
lipoprotein in exchange for triacylglycerols through the action of cholesteryl ester transfer protein 
(CETP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Lipoprotein metabolism adapted from (Dick et al., 2004). Abbreviations: CM, chylomicron; CR, 
chylomicron remnant; FC, free cholesterol; HL, hepatic lipase; LDL-R, LDL receptor; VLDL-R, VLDL receptor. 
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1.4.2 Apolipoproteins 
Apolipoproteins are a homologous gene family that is mostly expressed in liver tissue (Duchateau et 
al. 2001; Dayhoff, 1976). They are the major components of HDLs and LDLs so they are 
responsible for transporting fatty acids and cholesterol in the blood circulation and they bind 
receptors, which control the intake of the lipoproteins. Many apolipoprotein gene family members 
are located in gene clusters on different chromosomes (Myklebost and Rogne 1988; Karathanasis, 
1985). There are eight well-characterized apolipoproteins: APOA1, APOA2, APOA5, APOB, 
APOC1, APOC2, APOC3, and APOE. Some of them are already identified as PPAR target genes. 
Not so well known apolipoproteins are: APOA, APOC4, APOD, APOH, APOL (1-6), APOM, 
APOO and APOOL. Apolipoproteins and their lipoprotein particles are listed in table 3. 
Table 3. Apolipoproteins location, lipoprotein particles and regulation. 
Gene Chr 
PPAR targed 
(established) 
Lipoprotein particle 
APOA (LPA) 6 No LDL 
APOA1 11 Yes HDL 
APOA2 2 Yes HDL 
APOA4 11 Yes chylomicron, HDL 
APOA5 11 Yes chylomicron, VLDL, HDL 
APOB 2 No chylomicron, CM, LDL, IDL 
APOC1 19 No VLDL, HDL, LDL 
APOC2 19 No chylomicron, CR, IDL, VLDL
APOC3 11 Yes VLDL 
APOC4 19 No unknown 
APOD 3 No HDL 
APOE 19 Yes chylomicron, CR, IDL, VLDL
APOF 12 No HDL 
APOH 17 No cytoplasm 
APOL (1-6) 22 No HDL 
APOM 17 No HDL, LDL, TGRLP 
APOO X No unknown 
APOOL X No unknown 
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APOA (LPA) 
APOA is a highly polymorphic protein: its size varies over range of approximately 500 kDa due to 
number of tandem repeats (Kamboh et al. 1991). APOA links to LDL forming one disulfide bond to 
APOB-100 surface protein forming Lp(a) lipoprotein. Elevated plasma levels of Lp(a) are 
associated with increased risk for atherosclerosis and its manifestations: myocardial infarction, 
stroke and restenosis (Mancini et al., 1995). 
 
APOA family 
Apolipoprotein A1 is the major apolipoprotein of HDL and is a relatively abundant plasma protein. 
It is a single polypeptide chain with 243 amino acids (Brewer et al., 1978). The protein promotes 
cholesterol efflux from tissues to the liver for excretion (Zhang et al., 2003). It is a cofactor for 
lecithin cholesterolacyltransferase (LCAT), which is responsible for the formation of most plasma 
cholesteryl esters (Jonas, 2000). APOA1 is also isolated from prostacyclin stabilizing factor (PGI2), 
and thus may have an anti-clotting effect. Defects in the gene encoding APOA1 are associated with 
HDL deficiencies. Also APOA1 mimetics are suggested to substantially increase HDL cholesterol 
levels, which can be beneficial on cardiovascular events (Toth, 2007). Like apolipoprotein A1, 
APOA2 is a major apolipoprotein in HDLs. APOA2 controls the levels of free fatty acids in plasma. 
Mouse studies indicate that APOA2 plays a complex role in lipoprotein metabolism, with some 
antiatherogenic properties such as the maintenance of a stable HDL pool, and other proatherogenic 
properties, such as decreasing clearance of atherogenic lipoprotein remnants and promotion of 
insulin resistance (Weng and Breslow, 1996, Blanco-Vaca et al., 2001). Apolipoprotein A4 
(APOA4) is a component of chylomicrons and high-density lipoproteins. APOA4 protects against 
atherosclerosis by inducing cholesterol transportation from tissues to liver for elimination 
(Duverger et al., 1996). Apolipoprotein A5 (APOA5) is an important determinant of plasma 
triglyceride levels in an age-independent manner (Martin et al. 2003). It is a component of several 
lipoprotein fractions including VLDL, HDL and chylomicrons. It is believed that APOA5 affects 
lipoprotein metabolism by interacting with LDL-R gene family receptors. Notably, whole APOA 
gene family is referenced as PPAR targets (Vu-Dac et al., 1994; Vu-Dac et al., 1995, Prieur et al., 
2003, Nagasawa et al., 2007). 
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APOC family 
Apolipoprotein C1 (APOC1) is a specific inhibitor of cholesteryl ester transfer protein (CETP) 
(Gautier et al., 2002). CETP is a plasma protein that facilitates the transport of cholesteryl esters 
and triglycerides between the lipoproteins. It collects triglycerides from VLDL or LDL and 
exchanges them for cholesteryl esters from HDL (and vice versa). Apolipoprotein C2 (APOC2) is a 
necessary cofactor for the activation of lipoprotein lipase, the enzyme that hydrolyzes triglycerides 
in plasma and transfers the fatty acids to tissues. Apolipoprotein C3 (APOC3) is a VLDL protein. 
APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of 
triglyceride-rich particles. It is up-regulated by the NRs REV-ERBα and RORα and down-regulated 
by PPARs (Coste and Rodriguez, 2002). Moreover, the APOA1, APOC3 and APOA4 genes are 
closely linked in both rat and human genomes and transcription is controlled by a common 
enhancer (Zannis et al., 2001). Increase in APOC3 gene expression is associated development of 
hypertriglyceridemia (Vu-Dac et al., 1998). 
 
APOB 
Apolipoprotein B (APOB) is the primary apolipoprotein of chylomicrons and LDLs, but is also 
present in IDLs. It occurs in the plasma in two main forms, APOB-48 and APOB-100. The first is 
synthesized exclusively by the gut, the second by the liver. APOB-100 is present in LDLs and there 
it activates the LDL receptor, which starts LDL endocytosis. APOB-48 is generated, when a stop 
codon (UAA) is created by RNA editing as a result of the human APOB mRNA editing protein 
(BEDP). APOB-100 and APOB-48 share a common N-terminal sequence, but APOB-48 lacks 
APOB-100's C-termin. It is well established that high APOB-100 levels are associated with 
coronary heart disease, and are even a better predictor than the LDL level (McCormick et al., 1996, 
Farese et al., 1995). 
 
APOD 
Apolipoprotein D (APOD) is an atypical apolipoprotein and, based on its primary structure is a 
member of the alpha (2 mu)-microglobulin protein family of carrier proteins, also known as 
lipocalins (Pervaiz and Brew, 1987). APOD can bind cholesterol, progesterone, pregnenolone, 
bilirubin and arachidonic acid, but it is unclear if anyof these represent its physiological ligands. 
APOD is a protein component of HDLs in human plasma, comprising about 5 % of total HDL 
(Fielding and Fielding, 1980). APOD is closely associated with the enzyme LCAT (Jonas, 2000). 
The APOD gene is expressed in many tissues, with high levels of expression in spleen, testes and 
brain. It is associated with increased risk of breast cancer. It also accumulates at sites of 
regenerating peripheral nerves and in the cerebrospinal fluid of patients with Alzheimer's disease. 
APOD may, therefore, participate in maintenance and repair within the central and peripheral 
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nervous systems. APOD is likely to be a multi-ligand, multi-functional transporter. There are 
evidences that APOD could transport a ligand from one cell to another within an organ, scavenge a 
ligand within an organ for transport to the blood or transport a ligand from the circulation to 
specific cells within a tissue (Rassart et al., 2000). 
 
APOE 
Apolipoprotein E (APOE) is a main apopliporotein of chylomicrons and VLDLs. Chylomicron 
remnants and VLDL remnants are rapidly removed from the circulation by receptor-mediated 
endocytosis in the liver and peripheral cells. There are seven currently identified mammalian 
receptors for APOE, which belong to the evolutionarily conserved LDL receptor gene family. 
APOE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE 
gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2 genes. More recently, it 
has been studied for its role in several biological processes not directly related to lipoprotein 
transporting, including Alzheimer's disease, immunoregulation and cognition (Saunders et al., 1993; 
Corder et al., 1993; Van den Elzen et al., 2005).  
 
APOF 
Apolipoprotein F (APOF) is one of the minor apolipoproteins in human plasma (Olofsson et al., 
1978). It is part of HDL and its subfractions. Cholesterol ester transfer protein (CETP) moves 
triglyceride and cholesteryl ester between lipoproteins. APOF adjusts the action of CETP by 
controling CETP-facilitated lipid flux among HDL subfractions. APOF inhibits VLDL to HDL2 
transfer to one-half of the rate of VLDL to LDL and it stimulates the VLDL to HDL3 transfer. 
Moreover, APOF directs CETP-mediated remodelling of HDL3 and HDL2 particles in subclass-
specific ways, so APOF is important regulator of HDL metabolism (Paromov and Morton, 2003). 
 
APOH 
Apolipoprotein H (APOH), previously known as β2-glycoprotein I or beta-2 glycoprotein I, is a 
multifunctional apolipoprotein (Nakaya et al. 1980). One of its functions is to bind cardiolipin in 
mitochondrial inner membrane. When bound the structure of cardiolipin and APOH both undergo 
large changes in structure (Borchman et al., 1995). APOH has been implicated in a variety of 
physiologic pathways including lipoprotein metabolism, coagulation, inhibition of serotonine 
release and the production of anti-phospholipid autoantibodies (Shi et al., 2004, Sanghera et al. 
1997, Nimpf et al., 1985). 
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APOL 1-6 
Apolipoprotein L (APOL) proteins belong to the HDL family, which plays a central role in 
cholesterol transport. The six APOL genes are clustered on chromosome 22q12.3 and are the result 
of tandem gene duplication, whereas APOL5 and APOL6 are more distantly located. The APOL1-
APOL4 cluster might contribute to the substantial differences in the lipid metabolism of humans and 
mice (Monajemi et al., 2002). Also there are evidences anti-parasite effects of APOL1 protein 
(Shiflett et al., 2005).  
 
APOM 
Apolipoprotein M (APOM) is a minor component of HDLs and LDLs as well as triglyceride-rich 
lipoproteins (TGRLP) (Xu and Dahlbäck 1999). It has two transcript variants. APOM is important 
for the formation of pre-beta-HDL and cholesterol efflux to HDL and thereby inhibits formation of 
atherosclerotic lesions (Wolfrum et al., 2005). APOM is also associated with Alzheimer's disease 
(Kabbara et al., 2004). APOM gene is a direct target of liver receptor homolog-1 (NR5A2), which is 
an orphan NR (Venteclef et al., 2008).  
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2. Aims of the present study 
Information regarding PPAR binding-site specificity is complete, but it has not been extensively 
tested in practise (Heinäniemi et al., 2007). Testing of this in silico method at the example of the 
regulation of the apolipoprotein gene family by PPARs is the focus of this study. The specific aims 
are: 
1. Collect precise and more extensive data for comparison of the in silico screening and in vitro 
methods. 
2. Perform an in silico screening to identify new and established PPREs from apolipoproteins 
genes. 
3. Measure the expression level of all 23 apolipoproteins by quantitative real-time PCR in response 
to different PPAR agonist in different human cell lines. 
4. Perform chromatin immunoprecipitation (ChIP) assay, in order to study the association of PPAR 
and RXR with the apolipoproteins gene TSS and their association with other factors, such as CoAs, 
mediators and p-Pol II  
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3. Material and methods 
3.1 Materials 
Ligands 
NR ligands used in the studies were GW7647 [2-(4-(2-(1 
cyclohexanebutylcyclohexyllureido)ethyl)phenylthio)-2 methylpropionicacid] (Alexis 
Biochemicals, San Diego, CA, USA), rosiglitazone [5-[4-[N-methyl-N-
(2pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione] (Dr. M.W. Madsen, LEO Pharma, Ballerup, 
Denmark) and GW501516 [2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)1,3thiazol-5-yl)-
methylsulfanyl)phenoxy-acetic acid] (Alexis Biochemicals, San Diego, CA, USA). All these 
ligands were diluted in DMSO. 
Cell culture 
HEK293, THP-1 and HepG2 cell lines were grown in medium that was supplemented with 2 mM 
L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin. Cells were grown in humidified 95 
% air / 5 % CO2 incubator. HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containig 10 % fetal bovine serum (FBS). THP-1 and HepG2 were cultured in Roswell 
Park Memorial Institute’s medium (RPMI 1640) containing 10 % FBS. When split for experiment, 
the cells were grown overnight in phenol-red free DMEM supplemented with 5 % charcoal-stripped 
fetal bovine serum (FBS). FBS was stripped of lipophilic compounds by stirring it with 5 % (w/v) 
activated charcoal (Sigma-Aldrich) for 3 h at room temperature (RT). Charcoal was then removed 
by centrifugation and sterile filtration. 
 
3.2 Methods 
3.2.1 Ex vivo methods 
RNA extraction 
Cells were seeded into 6-well plates and grown overnight to reach a density of 60–70 %. The cells 
were stimulated with either GW7647, rosiglitazone, GW501516 or DMSO at a concentration of 100 
nM. Total RNA was isolated from the cells using RNAeasy kit (ZymoReaserch, HiSS Diagnostics 
GmbH, Freiburg, Germany) as instructed by the manufacturer. Total RNA amount was quantified 
(NanoDrop ND-1000, NanoDrop, USA). 
cDNA synthesis 
cDNA was synthesized using 1 μg of total RNA as template. The primer used was 100 pmol of 
oligodT18. cDNA was synthesized with 40 U of MMLV reverse transcriptase (Fermentas, Vilnius, 
Lithuania) and RNA degradation was prevented with 40 U of RNase inhibitor (Fermentas). The 
reaction mixture included also 4 μl 5 mM dNTPs, 2 μl 0,1 M DTT, 8 μl 5 x reverse transcriptase 
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buffer (250 mM Tris-Hcl (pH 8,3), 250 mM KCl, 20 mM MgCl2, 50 mM DTT) and the reaction 
volume was adjusted to 40 μl with RNase-free water. The reaction mixture was placed in 37 °C for 
1 h. After reaction was complete, the mixture was heated to 85 ºC at 10 min. The synthesized 
cDNA was diluted with sterile water to a volume of 400 μl. 
Real-time quantitative PCR 
Real-time quantitative PCR was performed in a IQ-Cycler 4 (BioRad) using the dye SybrGreen 
(Molecular Probes, Leiden, Netherlands) and the following reaction set up: 
2 μl 10 x buffer (HotStart PCR buffer (Fermentas)) 
2.4 μl 25 mM MgCl2 
0.4 μl dNTPs (10 nM) 
1.2 μl SybrGreen (1:2500 dilution from stock) 
0.15 μl HotStart DNA polymerase (5 U/μl) 
4.8 μl H2O 
4 μl template cDNA 
5 μl primer mix (0.8 μM) 
 
For PCR the following program was used: 
1. Denaturation for 5 min at 95 ºC 
2. PCR amplification repeated for 40 cycles 
 Denaturation for 30 s at 95 ºC 
 Annealing for 30 s at primer-specific annealing temperature 
 Elongation for 40 s at 72 ºC 
3. Final elongation for 10 min at 72 ºC 
4. Denaturation for 1 min at 95 ºC 
5. Melt curve analysis with 0.5 ºC decrease in 70 temperature steps 
 
The control gene used was acidic riboprotein P0 (ARP0, also known as 36B4). Fold inductions 
were calculated using the formula 2-(ΔΔCt), where (ΔΔCt) is the ΔCt(treatment)-ΔCt(solvent), ΔCt is 
Ct(gene)-Ct(ARP0) and Ct is the cycle, at which the threshold is crossed. PCR product quality was 
monitored using a post-PCR curve analysis at the end of amplification cycles. PCR-primer and used 
temperatures are listed in table 4. 
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Table 4. Primers and temperatures for real-time PCR 
gene Primer pairs (5'-3') Temperature (°C) Product size (bp) 
APOA CAGGACTGAATGTTACATCAC CTTCTCGAAGCAAACCAGAG 56 123 
APOA1 GTGCTCAGATGCTCGGTGG AGAAGAAGTGGCAGGAGGAG 60 273 
APOA2 CTCCATCAGGTCCTTGCCATA GCAACTGTGCTACTCCTCACC 60 135 
APOA4 CTCACCCAGCAACTCAATG GAGCTCCTCCACGTTCTG 58 214 
APOA5 CACCCATACGCCGAGAGC CCTTCCTCAGTCCCAGTGC 60 326 
APOB CATGGATATGGATGAAGATGAC CACTCAGCATTGTTCTGCAG  58 245 
APOC1 CAGACGTCTCCAGTGCCTTG GTCCTCATGAGTCAATCTTGAG  60 152 
APOC2 GAACCTGTACGAGAAGACATAC GAGGAGGATGCAAGAGCTAC  60 320 
APOC3 CATGCAGGGTTACATGAAGCAC GTAGGAGAGCACTGAGAATAC 60 325 
APOC4 CAGAAATGTCCCTCCTCAG CATCATCCTACCTCAGCCTC  60 113 
APOD AATCAAATCGAAGGTGAAGCCA ACGAGGGCATAGTTCTCATAGT 60 131 
APOE GCAAGCGGTGGAGACAGAG CCTCAGTTCCTGGGTGACC      60 156 
APOF TGGTCATCAGAAGGTCATATCCC AGAGGACTGTGAGAATGAGAAGG 60 182 
APOH AACGTAGGTATGGATGGTGGA CTGAATGGCGCTGATTCTGC 60 104 
APOL1 GCTTTTGATGACCAGGTCGTG CAGCCTTGTACTCTTGGAACC 60 133 
APOL2 GTCAGAGGAAGATCCCTTG CAGTCAGCAGTTGTAGCAG  60 224 
APOL3 GCAAGGGACATGATGCCAGA AAGAGTTTCCCCAAGTCAAGAGG 62 151 
APOL4 GTCAGTGCTGGTTGCAGTC CAGAGGAAGATCCCTTGGAG 60 289 
APOL5 AGCTCAAACTTGTGCAAAGGAA TGATGAGGCTGGTATGCTGTC 60 135 
APOL6 CAGATTTGCTGCCACAGAG GTGACATAGTCTGCCTTCTC 62 198 
APOM GAGCACAGATCTCAGAACTG CTCTTGATTCCTAGGAGTC 58 225 
APOO TTCGATTGACCCTCAGGAACT GCTTGCTCACCTTCAAAGTCT 60 109 
APOOL CTTGCCAACAGAACTCAGCTC CTTCTACCTAAGTCTCCTCATC 60 201 
RPLP0 AGATGCAGCAGATCCGCAT GTGGTGATACCTAAAGCCTG 56-62 318 
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siRNA transfection 
HepG2 cells were seeded into 6-well plates and grown overnight to reach a density of 30–40 %. 1.1 
μl of each siRNA subtype (6 µg/ml) (Eurogentec, Liege, Belgium) or 2 μl siRNA control (20 
µg/ml) (stealth siRNA) (Eurogentec) was mixed with medium (DMEM, 1 % glutamine) to get total 
volume of 250 μl. Transfection reagent (Mix Lipofectamin™, RNAiMAX, Invitrogen) (10 μl) were 
mixed with medium (DMEM, 1% glutamine) (490 μl) and incubated 5 min at RT. Transfection 
reagent mixed with medium were mixed with PPAR siRNA and control siRNA to get a total 
volume of 500 μl and incubated 20 min at RT. Medium was removed from the cells and fresh 
medium (DMEM, 1 % glutamine) was added (1.5 ml). PPAR siRNA and control siRNA medium 
mixes were added to the cells (500 μl).Total siRNA supply was 200 pmol/well. Medium containing 
serum (20 % FC, DMEM, 1 % glutamine) was added after 6 h of incubation (500 μl). 
RNA extraction, cDNA synthes and PCR performed as described earlier. Fold inductions were 
calculated using the formula 2-(ΔΔCt), where (ΔΔCt) is the ΔCt(treatment)-ΔCt(solvent), ΔCt is Ct(gene)-
Ct(ARP0) and Ct is the cycle at which the threshold is crossed. PCR product quality was monitored 
using a post-PCR curve analysis at the end of amplification cycles. 
 
Chromatin immunoprecipitation assay 
Cells were seeded into bottle and grown overnight to reach a density of 60–70 %. At the start of the 
experiment the medium in the bottles was reduced to 10 ml. The cells were stimulated with 
GW7647 ligand at a final concentration of 100 nM. 
Cross-linking of proteins and DNA 
Formaldehyde was added to culture medium to cross-link proteins bound to DNA as follows: 
270 μl formaldehyde (final concentration of 1 %), incubating for 5 min at RT with 1.5 ml lysine (1 
M), incubating for 5 min in RT (to stop cross-linking). 
The medium was removed and the cells washed twice with ice-cold PBS. Subsequently, the cells 
were scraped two times into ice-cold PBS (5 ml) and centrifuged for 5 min at 700 g at 4 ºC. 
Lysis of cells and sonication 
After centrifugation the cell pellet was resuspended in 1 ml of lysis buffer (1 % SDS, 10 mM 
EDTA, 50 mM Tris-HCl, pH 8.1) supplemented with a protease inhibitor cocktail (Roche). Lysis 
was performed for 10 min at RT. The lysate were sonicated to result in DNA fragments ranging 
from 200 to 400 bp in lengh (Diagenode Bioruptor, Liege, Belgium). Cellular debris was removed 
by centrifugation from 15 min at 20 000 g at 4 ºC. 
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Immunocollection 
The lysates were diluted 1:10. The following incubation was carried out in presence of specific 
antibodies: 
100 μl of undiluted lysate 
5 μl (Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA) 200 μg/ml MED1, PPARα, 
RXRα, PCG-1α, p-Pol II) antibody 
or 
1 μl (Normal Rabbit IgG, Upstate Biotechnology Inc. (Lake Placid, New York, USA) 1000 μg/ml,  
IgG) antibody 
2.4 μl sonicated salmon’s sperm (10 mg/ml) 
500 μl ChIP Dilution Buffer (0.01 % SDS, 1.1 % Triton-X 100. 1.2 mM EDTA, 16.1 mM NaCl,  
freshly added protease inhibitors (Roche), 50 mM Tris-HCl, pH 8.1) 
Incubation overnight on a rocking platform at 4 ºC. 
For input sample, 25 μl of undiluted lysate was diluted with 475 μl ChIP dilution buffer and the 
processing of these samples was continued with reverse cross-linking and DNA extraction as 
described below. 
Collection of the immunocomplexes 
For blocking of Protein A magnetic beads, their buffer was replaced of equal volume of Dilution 
Buffer and 100 μg/ml of sonicated salmon sperm DNA. They were incubated overnight rotating 
platform at RT. The immune complexes were collected with 25 μl of blocked MagaCell® Protein A 
magnetic beads (Fitzgerald Industries International, Concord, Maine, USA). 
Elution and reversal of cross-linking 
Elution of immunocomplexes was performed twice with 250 μl of elution buffer (25 mM Tris-HCl 
pH 7.5, 10 mM EDTA, 0.5% SDS) for first elution Protein A magnetic beads were incubated at 65 
ºC for 30 min. A second elution was performed for 2 min at RT. Cross-linking was reversed by an 
over night incubation at 64 ºC with 2.5 μl of Proteinase K (900 U/ml; Fermentas). 
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DNA extraction 
The DNA was extracted by adding 500 μl of 25/24/1 phenol/chloroform/isomyl alcohol followed by 
5 min a centrifugation at 20 000 g at RT. DNA was recovered from the aqueous phase using pipette. 
DNA was precipitated with 0.1 volumes of 3 M sodium acetate, pH 5.2 and 2 volumes of ethanol 
(ice cold) using 1 μl of glycogen (20 mg/ml, Fermentas) as carrier. Samples were centrifuged 20 
min at 14 000 rpm at RT. Supernatant was removed and pellets were washed with 500 μl of 70 % 
ice cold ethanol followed by 10 min centrifugation at 14 000 rpm at RT. DNA pellets were air dried 
and resuspented in water (input sample: 200 μl, output sample: 50 μl). 
 
PCR of chromatin templates 
PCR conditions for the different primers are described in table 5. PCR reactions were performed in 
an IQ-Cycler 4 using the dye SybrGreen. The following reaction was set up: 
 
2 μl 10 x buffer (HotStart PCR buffer (Fermentas). 
2.4 μl 25 mM MgCl2 
0.5 μl dNTPs (10 nM) 
1 μl SybrGreen (1:2500 dilution from stock) 
0.3 μl HotStart DNA polymerase (5 U/μl) 
7.5 μl H2O 
4 μl template cDNA 
5 μl primer mix (0.8 μM) 
 
The PCR program performed as described earlier. Products were resolved on 2 % TAE (200 mM 
Tris-HCl pH 7.5, 100 mM acetate, 5 mM EDTA) gel. The gels were imaged with Fuji FLA3000 
reader using ImageGauge software. The melt curve analysis combined with gel imaging allowed the 
detection of specific primer-dimer-free PCR products that were used for calculation from Ct-values 
the quantitative data relative to controls. Output samples were first normalized to their inputs and 
subsequently the fold change relative to non-specific IgG background was calculated. The fold 
inductions were calculated using 2(ΔCt), were ΔCt is Ct(specific antibody)- Ct(IgG control antibody) 
and Ct is the cycle at which the threshold is crossed. Relative association level were calculated 
using 2-(10-Ct(output-input)). 
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Table 5. PCR primers and temperatures for ChIP RT-PCR 
gene Primer pairs (5'-3') Temperature (°C) Product size (bp) 
APOA 
CTTGTGTTCTACAGCCTCAC 
GACTAACTTTGGTCTCTTGATC  58 276 
APOA1 
CACATTGCCAGGACCAGTG 
CACTCATTGCAGCCAGGTG 58 241 
APOA2 
CATCACCATGAGTCTTCCATG 
CATTCCAACCTGGCTCTCTC 60 262 
APOA4 
GATCTGCTGTCAGCTTCCAC 
CAGGAGTGCCATCCAAAGAC 60 346 
APOC2 
CTGTCACTTGAGAGAAGGTTC 
CACAGTCATGGTTCCAACAC 58 311 
APOE 
GAGGGTGTCTGTATTACTGG 
GCTCTCCTGAGACTACCTG 58 353 
APOF 
CATAGAGGTTGAGTGTGTGAC 
CAAAGTGATAGGCTTCCAGATG 60 361 
APOM 
GTACTATGGAGTGGTTGCATC 
CAGAGTTGTCAGTTGACTGTG 60 288 
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3.2.2 In silico methods 
In silico screening of putative PPREs 
Genomic sequences spanning +/-10 kB around the TSS of the gene analyzed were extracted from 
the current database release (NCBI build 36, Ensembl release 48) of the human and mouse genome. 
Conservation of putative REs between human, mouse, rat, and dog was checked using the 
Vertebrate Multiz Alignment and Conservation track available from UCSC (NCBI releases: human 
36.1, mouse 36) (Blanchette et al., 2004). A PPRE was marked conserved, when the sequence was 
75% conserved in alignment location. This conservation definition allows a change or a gap in three 
nucleotides from native sequence. Conservation of surrounding sequence was checked 50 bp up- 
and downstream of the TSS: two occurrence of a continuous stretch of in minimum five matching 
bp was required to label the PPREs to be located within conserved surrounding sequence. The 
human and mouse sequences were screened from weak to strong putative PPREs using a classifier. 
The classifier was based on experimentally collected data from in vitro PPAR-RXR binding to 
DNA. Collected data was converted to simplified tables, which were used for in silico screening 
(Table 6) (Heinäniemi et al., 2007). 
 
Table 6. PPARγ's RE variants (according to Heinäniemi et al., 2007). First row shows REs sequence number from 
5'- start. Second row is the consensus sequence for PPARγ. Rows three to five shows departure from consensus 
sequence and theirs effect to the binding strength. 
 
% binding 1 2 3 4 5 6 7 8 9 10 11 12 13 
cons. (90-100) A/G G G T C/G A A A G G T C A 
class I (60-90)    C/G A/T  T G  T C/G A/G/T G 
class II (30-60) C/T A/T T A   C C A/C/T    C/T 
class III (0-30)  C A/C   C/G/T G T  A/C A   
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4. Results 
4.1 In silico analysis of the apolipoprotein gene family 
In order to find PPAR-regulated genes from the apolipoprotein gene family, we performed in silico 
screening to find putative PPREs. We analysed each gene in human and mouse at 10 kB of the 
genomic sequence up- and downstream of their respective TSS. In silico screening resulted in 
various numbers of putative PPREs. Therefore, we organized the genes according to strength and 
level of conservation of PPREs found (strong and conserved (SC), strong and conserved weak (S-
CW), strong (S) and weak (W)). Results are shown in figures 4 and 5. 
The six genes APOA1, APOA2, APOA4, APOA5, APOC3 and APOM have strong and conserved 
PPREs. APOA1, APOA2, APOA4, APOA5 and APOC3 are already known PPAR target genes. 
APOA4 has no mouse ortholog. APOM has the two conserved strong elements and several weak 
conserved elements. 
The strong and conserved weak element category has the four genes (APOA, APOC1, APOE and 
APOF), of which one (APOE) is an established PPAR target gene. APOA has no mouse ortholog. 
APOA and APOF have one strong and one conserved weak putative PPRE. APOC1 and APOE have 
the two strong and one conserved weak putative PPRE. There fore, APOC1 is a good candidate for 
a PPAR target gene. APOE gene's strong element is already known as an established PPRE. 
The nine genes APOD, APOL1, APOL2, APOL3, APOL4, APOL5, APOL6, APOO and APOOL are 
categorized in a strong element category. APOL4, APOL3 and APOL5 have no mouse ortholog. 
APOL2 has the four putative strong PPREs, but the mouse ortholog does not look too convincing. 
APOL1 has the three putative strong PPREs and the same pattern can be found in its mouse 
ortholog. APOL4 and APOO have the two strong putative REs. The remaining five genes (APOD, 
APOL3, APOL5, APOL6 and APOOL) each have the one strong putative PPRE. 
We found four genes (APOB, APOC2, APOC4 and APOH) in the weak category. APOB has three 
conserved PPREs and is so the most promising gene in this group. APOC2 and APOC4 are located 
very close in human genome and have only two conserved weak elements. APOH, which gene 
product is located usually in cytoplasm, has no conserved putative PPREs. 
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Figure 4. Overview of the genomic organization of the human and mouse genes APOA1, APOA2, APOA4, 
APOC3, APOM, APOA, APOC1, APOE and APOF (10 kB up- and downstream of their TSS) indicating putative 
PPREs and theirs relative strength (green, dark blue and light blue). Colored boxes are indicating the conservation 
degree of putative REs (yellow (conserved), orange (inside conserved area) and red (not conserved)) and letters species 
(M = Mus musculus, D = Canis familiaris, R = Rattus norvegicus and H = Homo sapiens). Genes are organised two 
groups: the first group has at least one conserved strong (CS) putative RE and second group at least one strong and 
conserved weak (S-CW) putative RE. 
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Figure 5. Overview of the genomic organization of the human and mouse genes APOD, APOL1, APOL2, APOL4, 
APOL5, APOL6, APOO, APOOL, APOB, APOC2, APOC4 and APOH (10 kB up- and downstream of their TSS) 
indicating putative PPREs and theirs relative strength (green, dark blue and light blue). Colored boxes are 
indicating the conservation degree of putative REs (yellow (conserved), orange (inside conserved area) and red (not 
conserved)) and letters species (M = Mus musculus, D = Canis familiaris, R = Rattus norvegicus and H = Homo 
sapiens). Genes are organised two groups: the first group has at least one strong (S) putative RE and second group has 
only weak (W) putative REs. 
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4.2 RT-PCR results 
HepG2, HEK239 or THP-1 cells were treated for 2, 4, 6 and 24 h with 100 nM of either the PPARα 
agonist GW7647, the PPARγ agonist rosiglitazone or the PPARβ/δ agonist GW501516, and RNA 
was extracted. The relative fold inductions of the mRNA amounts of the apolipoprotein genes and 
of known PPAR target genes (CPTI and PDK4) were determined by real-time quantitative PCR. 
Results are shown in figures 6, 7, 8, 9A, 9B and 10. For HepG2 and HEK293 cells we used 
established PPAR target gene CPT1A gene as a positive control and for THP-1 cells we selected the 
PDK4 gene.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Expression of the control genes in HepG2, HEK239 and THP-1 cells. Real-time quantitative PCR was 
used to determine the mRNA levels of the control genes (established PPAR target genes CPT1 and PDK4) in our three 
cellular models (HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6, and 24 h with 100 nM GW7647 
(PPARα agonist, green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist, 
light blue). Columns represent the means of at least three independent treatment and the bars represent standard 
deviations. Solid lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's 
t-test was performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent 
controls (* p<0.05, ** p<0.01, *** p<0.001). 
 
CPT1A shows an approximately 1.5-fold induction after 2 and 4 h with PPARα ligand in HepG2 
and HEK293 cells. In HepG2 cells the induction has the same strength and timing also with 
PPARδ/β ligand. The induction of gene expression with PPARγ ligand starts already at the first 
time point (1.5-fold) and continues up to a 3.3-fold change after 24 h. CPT1A in HEK293 cells with 
PPARγ ligand has a same trend as in HepG2 cells, but the induction is not so obvious. PDK4 in 
THP-1 cell line shows strong inductions. With PPARα ligand the fold induction is 3.1 to 6.1. PDK4 
induction with PPARγ ligand is less prominent, but an almost up to 3.0-fold induction can be seen 
after 2 and 6 h. With PPARδ/β ligand inductions after 2 h are already 8.1, 17.1-fold after 4 h and 
15.8-fold after 6 h. 
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Next we analyzed the apolipoprotein genes. Results from the apolipoprotein genes are sorted 
according to their classification in the in silico screening. First are the genes, which contain 
conserved strong (CS) putative PPREs (Figure 7). The second apolipoprotein group has strong and 
conserved weak (S-CW) genes (Figure 8). Third group has genes, which we establish one or more 
strong (S) PPRE (Figures 9A and 9B). The last and the smallest group have weak (W) PPREs 
containing genes (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Expression of the CS apolipoproteins genes in HepG2, HEK239 and THP-1 cells. Real-time quantitative 
PCR was used to determine the mRNA levels of the apolipoproteins (APOA1, APOA2, APOA4, APOC3, APOM,) in 
three cell line (HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6, and 24 h with 100 nM GW7647 (PPARα 
agonist, green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist light blue). 
Columns represent the means of at least three independent treatment and the bars represent standard deviations. Solid 
lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's t-test was 
performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent controls (* 
p<0.05, ** p<0.01, *** p<0.001). 
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The APOA1 gene is expressed in HepG2 cells and THP-1 cells. It has a significant fold induction 
with PPARα ligand, which is over 1.5-fold in HepG2 cells after 6 and 24 h and in THP-1 cells after 
4 and 24 h. APOA2, is expressed in HepG2 and HEK293 cells. It has a significant induction (over 
1.5-fold) with PPARγ ligand in HepG2 cell line after 4 and 24 h. APOA4 is expressed only in 
HepG2 cells and has no significant induction with any ligand. APOC3 is up-regulated with PPARα 
ligand and PPARγ ligand. APOC3 responds after 4 and 6 h to all PPAR ligands and in addition after 
24 h to PPARγ ligand. APOM is not responding to any ligand in any cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Expression of the CS apolipoproteins genes in HepG2, HEK239 and THP-1 cells. Real-time quantitative 
PCR was used to determine the real time mRNA levels of the apolipoproteins (APOA, APOF, APOE, APOC1,) in three 
cell lines (HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6, and 24 h with 100 nM GW7647 (PPARα 
agonist, green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist light blue). 
Columns represent the means of at least three independent treatments and the bars represent standard deviations. Solid 
lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's t-test was 
performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent controls (* 
p<0.05, ** p<0.01, *** p<0.001). 
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APOA is not responding to any ligand in any cell line. APOF is up-regulated with PPARα ligand in 
HepG2 and THP-1 cell lines and down-regulated with all ligands in THP-1 cell line. Up-regulation 
is seen after 4 and 24 h in HepG2 cell line and after 4 h in THP-1 cells. In THP-1 cells APOF is 
down-regulated 0.3-fold with all ligands after 2 h. APOE is responding to all ligands in HepG2 cells 
but has no response in HEK293 or THP-1 cell lines. With PPARα and PPARδ/β ligands APOE is 
up-regulated approximately 2-fold after 6 and 24 h. APOE is also responding to PPARγ ligand in all 
time points between 1.5- and 2.3-fold induction. APOC1 is responding in HEK293 and THP-1 cells 
but not in HepG2 cells. In both responsive cell lines APOC1 gets approximately 2.0-fold induced 
with all ligands after 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9A. Expression of the strong (S) apolipoproteins genes in HepG2, HEK239 and THP-1 cells. Real-time 
quantitative PCR was used to determine the mRNA levels of the apolipoproteins (APOD, APOL 1-3) in three cell lines 
(HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6, and 24 h with 100 nM GW7647 (PPARα agonist, 
green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist light blue). 
Columns represent the means of at least three independent treatments and the bars represent standard deviations. Solid 
lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's t-test was 
performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent controls (* 
p<0.05, ** p<0.01, *** p<0.001). 
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Figure 9B. Expression of the strong (S) apolipoproteins genes in HepG2, HEK239 and THP-1 cells. Real-time 
quantitative PCR was used to determine the mRNA levels of the apolipoproteins ( APOL 4-6, APOO, APOOL) in three 
cell lines (HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6 and 24 h with 100 nM GW7647 (PPARα 
agonist, green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist light blue). 
Columns represent the means of at least three independent treatment and the bars represent standard deviations. Solid 
lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's t-test was 
performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent controls (* 
p<0.05, ** p<0.01, *** p<0.001). 
 
APOD is expressed in HepG2 and HEK293 cells. A significant expression level is detected in 
HepG2 cells with all ligands. All ligands provide a 2.0-fold induction after 6 h. APOL1 is expressed 
in all three cell lines. In HepG2 cells with PPARα ligand APOL1 gets induced more than 1.5-fold. 
In HEK293 cells same kind of induction can be seen with all three ligands after 6 and 24 h. Down-
regulation is seen after 2 h in THP-1 cells. APOL2 shows only with PPARγ ligand in HepG2 cells 
after 24 h. APOL3 is expressed in all three cell lines. In HepG2 cells there is a 2-fold induction after 
2 and 24 h. The gene is induced also in HEK293 cells, but not with all ligands. PPARα ligand gives 
an approximately 2.0-fold induction after 6 and 24 h with the APOL3 gene. PPARγ ligand and 
PPARδ/β ligand shows the same induction after 24 h. APOL4 is only expressed in HepG2 cells and 
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is not ligand responsive. APOL5 is expressed in all three cell lines. In HepG2 cells there is a 2.0-
fold induction with PPARα and PPARδ/β ligand. There are also ligand effects with PPARγ ligand 
but only a 1.5-fold induction is observed. In HEK293 cells up-regulation can be seen with all three 
ligands. With PPARα and PPARγ ligand has earliest effect after 4 h and stays active through the 
other time points. With PPARδ/β ligand induction can be seen only after 24 h. In THP-1 cell line, 
there is a 0.6-fold down-regulation after 2 h with PPARγ ligand. APOL6 is expressed in HepG2 and 
THP-1 cells. In HepG2 cells only PPARα and PPARδ/β agonist treatment exceeds the1.5 threshold 
line (with PPARα ligand after 6 and 24 h and with PPARδ/β after 4 h). Approximately 1.7-fold up-
regulation can be also detected in THP-1 cells by PPARγ ligand. APOO and APOOL are expressed 
only in HepG2 cell line. APOO gene expression is not affected by PPAR ligands. APOOL is 
induced after 4 and 6 h with PPARα ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Expression of the CS apolipoproteins genes in HepG2, HEK239 and THP-1 cells. Real-time quantitative 
PCR was used to determine the mRNA levels of the apolipoproteins (APOB, APOC2 and APOH) in three cell lines 
(HepG2, HEK239 and THP-1). Cells were stimulated for 2, 4, 6 and 24 h with 100 nM GW7647 (PPARα agonist, 
green), 100 nM rosiglitazone (PPARγ agonist, dark blue) or 100 nM GW501516 (PPARδ/β agonist light blue). 
Columns represent the means of at least three independent treatments and the bars represent standard deviations. Solid 
lines indicate the threshold of 1.5-fold up-regulation or 0.5-fold down-regulation. Two-tailed Student's t-test was 
performed to determine the significance the mRNA induction by PPAR agonist in reference to solvent controls (* 
p<0.05, ** p<0.01, *** p<0.001). 
 
APOB is expressed only in HepG2 cells, where it shows a strange expression pattern. Afer 4 h the 
gene is down-regulated and up-regulated after 6 h with all ligands. APOC2 genes expression is not 
affected by PPAR ligands at any time point. APOH is expressed in HepG2 cell line but was not 
ligand responsive. APOC4 should be analysed in this category but expression was not detected in 
any of the cell lines. This same problem was encountered also in siRNA experiment. 
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4.3 siRNA results 
Next we made a siRNA experiment, where we silenced PPARα, PPARγ and PPARβ/δ in HepG2 
cells. After 48 h RNA was collected and real-time PCR experiments were performed for receptor 
genes (PPARα, PPARγ and PPARβ/δ) and the known target gene (CPT1A) (Figure 11) and 
apolipoproteins results are seen in Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effects of silencing PPARα, PPARγ and PPARβ/δ on control genes in HepG2 cell line. PPARα, PPARγ 
and PPARβ/δ were silenced from HepG2 cells with siRNA while cells transfected with non-specific siRNA were used 
as a control. Treatment was performed for 48h. Real-time quantitative PCR was used to determine the mRNA levels of 
the PPARα, PPARγ, PPARβ/δ and CPT1A genes. Columns represent the means of at least three independent treatments 
and the bars represent standard deviations. Solid broad lines indicate 100 and 60 %. Two-tailed Student's t-test was 
performed to determine the significance the mRNA chance by PPAR knockdown in reference to random RNA controls 
(* p<0.05, ** p<0.01, *** p<0.001). 
 
PPARα gene expression after siRNA treatment is 40 %, that of PPARγ only 15 % and that of 
PPARβ/δ is approximately 30 %. The remaining expression of the control gene (CPT1A) is 50 %. 
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Figure 12. Effects of silencing PPARα, PPARγ and PPARβ/δ on apolipoproteins in HepG2 cell line. PPARα, PPARγ and PPARβ/δ were silenced in HepG2 cells with 
siRNA, while cells transfected with nonspecific siRNA were used as a control. Treatment was performed for 48 h. Real-time PCR was used to determine the mRNA levels of 
the apolipoproteins. Columns represent the means of at least three independent treatments and the bars represent standard deviations. Solid broad lines indicate 100 and 60 %. 
Two-tailed Student’s t-test was performed to determine the significance the mRNA chance by PPAR knockdown in reference to random RNA controls (* p<0.05, ** p<0.01, 
*** p<0.001). 
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APOA gene expression seems to be unchanged after siRNA treatment. The expression of APOA 
family is generally going down with the exception of APOA1, which expression level is almost 
unchanged. APOA2, APOA4 and APOA5 are clearly going down by 60 %. In the APOC family 
APOC3 is not reacting to siRNA treatment but APOC2 goes down to 30 %. APOC1 is between of 
APOC3 and APOC2 and is down-regulated to 60 %. Also APOB and APOD expression goes down 
approximately to 50 %. The APOE gene expression is down to 40 %. APOF expression went to 
down to approximately 40 %. One good example of genes, whose expression remains unchanged, is 
APOH. The reaction of siRNA treatment in the APOL family is variable. APOL1, APOL2 and 
APOL6 are going down nearly 50 % but APOL4 genes expression is going up to 120 %. APOL3 
and APOL5 expression is unchanged. The same observation was made for APOM and APOOL 
genes. Surprisingly, APOO gene goes down 40 %. 
 
4.4 ChIP results 
Next we examined in HepG2 cells, whether PPARα, RXRα, p-Pol II, the mediator proteins 
TRAP220 or the CoA PGC-1α were located to the TSS regions of selected genes (APOA, APOA1, 
APOA4, APOA2, APOC2, APOF, APOE and APOM). APOA1, APOA4, APOA2 and APOE were 
serving as positive control because they are already established PPAR target genes. APOM and 
APOA genes were serving as negative control because expression chances were not detected during 
quantitative PCR or siRNA experiments. The APOF gene was selected from conclusion of 
promising quantitative PCR results and its evident importance in HDL metabolism. The APOC2 
gene was selected from conclusion of promising siRNA results and its role as cofactor of LPL. 
Chromatin was extracted from HepG2 cells, which had been treated for 0 min, 120 min or 240 min 
with 100 nM GW7647 and then cross-linked in the presence of formaldehyde. ChIP experiments 
were performed with anti-PPARα, anti-RXRα, anti-p-Pol II, anti-TRAP220, anti-PGC-1 antibody 
and IgG was used as negative control. The genomic DNA fragments that were recovered from 
reverse-cross-linked chromatin served as templates for PCR reactions with primers specific for the 
TSS containing the PPRE responsive TSS and control TSS's. There was several problems with the 
ChIP protocol so results are unreliable (data is not shown). 
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5. Discussion 
This is the first study of the responsiveness of all apolipoproteins to PPAR ligands in HepG2, 
HEK239 and THP-1 cells. In addition, we investigated the effect of silencing PPARs with siRNA 
on human hepatocellular cells. Also, we performed ChIP assay with selected genes. We used 
already established PPAR target genes as a positive control. 
 
In silico analysis 
In this study an in silico screening for putative PPREs around the apolipoprotein genes was 
performed (Figures 4 and 5). Traditionally, REs have been searched from the promotor regions 
relatively near the TSS and in the 5’-flanking regions of target genes, but recently also more distal 
functional REs have been discovered (Kim et al., 2006). Also the 3’-untranslated regions and 
introns cannot be neglected in the search for REs (Prieur et al., 2003). Present understanding is that 
functional PPREs can be located several tens or even hundreds of thousands base pairs away from 
the target gene's TSS and either on the up- or downstream side. Recent discoveries have also 
proven that even interchromosomal interactions in NR-mediated gene regulation are possible and 
necessary for the transcription of certain genes (Nunez et al., 2008). 
A normal weight matrix analysis usually gives strong background of false positive predictions 
(Stormo, 2000). Therefore, we used a more sophisticated search method, which is based on in vitro 
data of PPAR-RXR binding to PPREs. This sensitive method decreases the number of false positive 
PPREs. Whole genome ChIP-on-chip experiments have shown that strong NR bindig sites can be 
up- or downstream of the TSS and are usually located 10 kb region from TSS (Liu et al., 2007). 
Based on these facts we selected our in silico screening parameters. We searched up- and 
downstream from the TSS (10 kb) using an in vitro based in silico screen. The parameters have 
been proven to be effective in earlier research (Heinäniemi et al., 2007). 
In silico screening showed that already established PPAR responsive genes have at least one strong 
PPRE. We also found established PPREs in our in silico screening, such as the PPREs of APOA5 
and APOE genes, which were defined strong. We could also define established PPREs of APOC3 
and APOA2 genes, which were defined weak, but we were unable to confirm the PPRE of the 
APOA1 gene (Vu-Dac et al., 1994, Vu-Dac et al., 1995, Krey et al., 1993, Prieur et al., 2003, 
Galetto et al., 2001). Furthermore, findings in strong and weak element categories were promising. 
At least the amount and quality of elements found and genes reference to metabolism correlates 
generally well. In strong RE category there were three from five genes responding to PPAR ligands. 
Strong and conserved weak category genes had two from four genes and strong category five from 
nine genes responding to the PPAR ligands treatments. Surprisingly there was also one gene from 
three in weak category which was responding to ligands. A trend can be detected where number and 
quality of found putative PPREs correlate with the number of responsive genes in the groups (CS, 
S+CW, S and W) in the following order W<CS<S+CW<S. CS genes category result do not fit in 
this pattern. Possible explanation would be competition between NRs for REs, which are in this 
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group quite near to consensus sequence. Strong category also probably beats other categories being 
the larges groups in this study. 
We found several conserved strong PPREs in APOM gene, but it was unresponsive to PPAR 
ligands. APOM gene is an established target of liver receptor homolog-1 (LRH-1) and it is possible 
there is competition for the REs between PPAR and LRH-1 (Venteclef et al., 2008). However, 
established LRH-1 REs are not overlapping with putative PPREs, which we found, and it is not 
uncommon that gene is regulated by several NRs. For example, APOA1 gene transcription has been 
show to be modulated by various NRs, such as ARP-1, HNF-4α, PPARα and LRH-1 (Ladias and 
Karathanasis, 1991, Vu-Dac et al., 1994, Sladek et al., 1990, Delerive et al., 2004). Nevertheless, 
there can also be competition for the REs between NRs. This competitive or cooperative regulation 
is possible at least between PPARs and HNF-4α (Prieur et al., 2005). This kind of regulation is still 
impossible to predict from in silico screening results. Experimental methods, like quantitative PCR 
and ChIP, have to confirm these REs. 
 
Real-time PCR 
Real-time PCR experiments were performed in three cell lines. Cell lines were selected according 
to representativeness of key tissues in apoliprotein physiology. Human hepatocellular cells 
(HepG2) are representing liver tissue. Liver is considered the major tissue where apolipoproteins 
are expressed. Assembly and necessary modifications of the major lipoproteins of blood like HDL 
and VDL takes place in liver, also many receptors, which are responsible for uptake of chylomicron 
remnants and HDL are present there. The regulation of the receptor genes would also be an 
interesting research project. HEK293 cell line, which is derived from human embryonic kidney 
cells represents kidney tissue in this study. This cell line is not a cancer cell line and so it rather 
resembles normal tissue. PPARδ/β is highly expressed in kidney, so that it may be the dominant 
PPAR subtype responsible for the regulation of apolipoprotein expression. Although 
apolipoproteins should not be expressed in kidney, we found for the genes APOL5 and APOC1 an 
interesting up-regulation. The human acute monocytic leukemia cell line (THP-1) represents a pre-
stage of macrophages and therefore cells of the immune system. Generally, detected expression 
levels were weak in this cell line. When we observed up-regulation in HepG2 or HEK293 cells 
there was usually a down-regulation in THP-1 cells. Using those three cell lines we were looking 
for tissue wide expression regulation of PPARs. 
From the real-time PCR results in the conserved and strong category, it was not so evident that any 
established PPAR target gene is regulated by PPARs (Figure 7). Best results are seen with APOA1 
and APOA2 genes, where up-regulation is seen after 6 and 24 h. However, there are also several 
controversial time points, where standard deviations were notable high. THP-1 cell line seems to 
provide most unreliable results. The best situation would be, to use primary cells, in order to avoid 
possible problems, which are typical for cancer cell lines. Furthermore, the statistically significant 
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up-regulation of the APOC3 gene is in contrast with the literature, where it is referred to be down-
regulated by PPARα (Hertz et al., 1995).  
Real-time PCR results with the APOE gene from the strong and conserved weak category are 
evident. This gene is directly regulated by PPARs (Figure 8). Another interesting gene is APOF, 
which is down-regulated in THP-1 cells. But we also detect expression cycling in APOF gene, 
which we cannot explain. There is down-regulation after 2 h with all ligands and then significant 
up-regulation after 4 h. This is an unusual expression pattern. There is also observed up-regulation 
with PPARα agonist in HepG2 cells. It would be worth to repeat the experiment with higher 
resolution, for example with more time points and shorter intervals. This would verify, whether 
PPAR ligands have any real effect on APOF gene expression. As mentioned earlier in the literature 
review, APOF is a regulator of HDL metabolism (Paromov and Morton, 2003). Using PPAR 
antagonist it would be possible to up-regulate the APOF gene and so amount of HDL. This could 
help patients with high cholesterol or atherosclerosis. Another interesting gene in this group is 
APOC1. APOC1 is a specific inhibitor of CETP (Gautier et al., 2002). Therefore, like the APOF 
gene, also APOC1 is controlling metabolism of lipids and so it is logical to think that APOC1 could 
be a target of PPARs. However, in the results APOC1 gene up-regulation occurred very late so it is 
possible that this is not a direct effect of PPARs. 
In the group of strong genes, there are five very interesting candidates (Figures 9A and 9B). The 
APOD gene, which is not a typical apolipoprotein since it rather belongs to lipocalins carrier 
proteins family, is one of them (Pervaiz and Brew, 1987). APOD is clearly up-regulated after 6 h. It 
is not clear, if this is direct effect of PPAR or secondary effect. It would be interesting to repeat the 
experiment with higher resolution to see when up-regulation really peaks. The APOL1 gene is the 
only member of the APOL gene family member, which has a known function. There is strong 
evidence of APOL1 protein being involved in anti-parasitic effects (Shiflett et al., 2005). Anti-
parasite effects, however, refer more to immune defence than to metabolism. Anyway, we observed 
PPAR regulation with all three cell lines. APOL1 and other specific surface proteins of HDL are the 
principle anti-microbial molecules. It has been shown that HDLs can serve as platform for the 
assembly of multiple synergistic proteins, which may play a critical role in the evolution of 
primate-specific innate immune system. APOL3, APOL5 and APOL6 gene expression pattern is 
really close to APOL1. Unfortunately, a specific function for APOL3, APOL5 or either APOL6 
genes has not been found. Nevertheless, similarity of expression patterns strengthens the 
assumption of shared TF structures of APOL gene family (Philippe et al., 2001). Maybe whole gene 
family is more related to the sophisticated immune defence of primates than to lipid metabolism but 
verifying that would need further experiments.  
In the group of weak genes, there were two very interesting genes (Figure 10). APOB gene which 
expression pattern first shows a significant down-regulation and then almost instantly up-regulation 
should be interpreted with reservation. Usually this kind of result is seen, when there is RNA 
degradation, already low expression levels, bad primers or reaction mixture problems. All those 
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factors impacts the efficacy of PCR reaction. Another interesting gene in this group is APOC2. 
APOC2, functioning as a cofactor of LPL and therefore as a regulator of fatty acid uptake in the 
liver, would be a logical PPAR activated gene whose expression is stimulated by dietary ligands. 
However, when looking at APOC2 genes expression pattern, there is unfortunately no observed 
ligand effect. It would be interesting to test if this gene is regulated by another NRs like, for 
example, apolipoprotein regulatory protein-1 (NR2F2). 
 
siRNA 
Known PPAR up-regulated genes (APOA2, APOA4, APOA5 and APOE) were significantly down-
regulated with siRNA against PPARs (Figure 12). However, APOA1 and APOC3 expression 
remains unchanged. APOC3 gene expression is up-regulated by REV-ERBα and RORα and down-
regulation is seen with PPARα agonist (Coste and Rodriguez, 2002). In siRNA experiments no 
ligands were used, so it is possible that up-regulation was not seen for this reason. APOA1 gene is 
the major apolipoprotein and is promoting cholesterol efflux from tissues to the liver for excretion 
(Zhang et al., 2003, Jonas, 2000). It seems that APOA1 expression is safeguarded against effects of 
missing PPARs. Indeed, after knock-down of PPARs there are left three NRs (ARP-1, HNF-4α and 
LRH-1) to regulate APOA1 gene and even one of those binds DR1 (HNF-4α) elements (Ladias and 
Karathanasis, 1991, Sladek et al., 1990, Delerive et al., 2004, Prieur et al., 2005). Also the RNA 
extraction time is long, 48 h, so there is plenty of time to activate and compensate lack of PPARs. 
APOM expression level is not moving. This is further supporting that the PPREs found are not for 
PPARs at all. A good candidate would be the NR HNF-4α, which binds DR1 type REs (Prieur et 
al., 2005). 
Many interesting genes were significantly down-regulated (APOB, APOC1, APOD, APOC2 and 
APOL1,2,6) which provides evidence of PPAR regulation by direct or secondary effects. APOB 
gene, which was giving strange but statically significant results from quantitative PCR, is now 
clearly down-regulated. Also same kind effects are seen interestingly for APOC1, APOD and 
APOC2 genes. Unfortunately, this experiment is not giving any more proof that APOC2 is a direct 
target of PPARs, whereas the regulation of the APOL genes family members by PPARs gained 
more confirmation from the siRNA experiment. After siRNA treatment there are three genes 
affected and one more almost affected. APOL1, APOL2 and APOL6 genes are going down 
statistically significantly. APOL4 gene seems down-regulated by PPARs but unfortunately the 
effect is not statistically significant. This effect could be checked by using some PPAR agonist 
combined with a siRNA experiment. 
The APOO gene seems affected by siRNA treatment, but we can only presume that this is a 
secondary affect. Fibroblast growth factor 21 (FGF21) is direct target of PPARα. Its function is to 
stimulate lipolysis in white adipose tissue. FGF21 has been reported to be the key regulator of 
lipids and their efflux (Inagaki et al., 2007, Micheal et al 2007). This gene is affecting whole lipid 
metabolism pathway and so it also might mediate the expression levels of apolipoproteins and 
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create artefacts in the siRNA experiment. The siRNA results do not proof a direct regulation by 
PPARs. However, when results are combined with the real-time PCR results, we can see short time 
depended regulation there is strong evidence to suggest direct regulation by PPARs. 
 
ChIP 
We performed chromatin immunoprecipitation (ChIP) assay in human hepatocellular cells which 
we believed to represent well liver tissue. Unfortunately, we had difficulties with the ChIP assay. 
We wanted to study the association of PPAR and RXR with the APOA1, APOA2, APOA4, APOE, 
APOA, APOC2, APOF, APOL6 and APOM TSS and in addition the association with other factors, 
such as CoAs, mediators and p-Pol II. Binding of those factors in the TSS was not confirmed by 
ChIP assays. Either the antibodies used were not specific enough or the conditions of the protocol 
were not ideal for their function. Also it is possible that some mistakes were made during the 
protocol causing errors in results. To improve reliability of ChIP protocol more controls would be 
needed, for example adding at least one certain positive and negative region. Also use of technical 
duplicates or triplicates would improve reliability of the results. There are also plenty of antibodies 
on the market from different companies. It would be worth to try some other antibodies like Upstate 
Biotechnology's or Abcam’s. Because the basic ChIP protocol did not work, it was not worth to 
even try chromatin conformation capture (3C) assays. This assay would be needed to see, whether 
PPREs really a loop to the TSSs and what is the kinetics of this possible looping. The differences in 
general signal strength between different TSS regions shows a trend, but without statistical 
significance no clear conclusions can be drawn. 
 
In summary 
In summary, the APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and 
APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Moreover, a 
trend can be detected where number and quality of found putative PPREs correlate with the number 
of responsive genes. In addition, results have provided new insights into the understanding of lipid 
metabolism on gene regulation level that apply to many typical diseases of industrial countries.  
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